Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas
Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas
复制标题
卡麦角林治疗催乳素大瘤期间的系列 3 T 磁共振成像
作者：
M. Kurosaki;A. Kambe;Takashi Watanabe;S. Fujii;T. Ogawa
摘要目的：卡麦角林是治疗催乳素(PRL)产生的垂体腺瘤的首选药物，因为它能使PRL水平正常化，并使肿瘤缩小。近年来，3T磁共振成像(3T MRI)用于神经成像的临床应用迅速扩大。特别是，T2加权成像(T2WI)提供了高的解剖和对比分辨率。患者和方法：在本研究中，10例巨大催乳素瘤患者在卡麦角林治疗过程中使用了序列3T磁共振T2WI。卡麦角林以标准的每周剂量开始，并根据个人治疗后的PRL值进行增量调整。结果：MRI证实所有患者在卡麦角林治疗期间肿瘤缩小。除一名患者外，卡麦角林使所有患者的高催乳素血症恢复正常。在10例患者中，6例在T2WI上整个腺瘤均有明显的低信号区。在这6名患者中，有4名患者在1-4个月时出现大量低信号区域，之后肿瘤体积缩小了80%以上。在催乳素瘤治疗的早期阶段，这些发现预示着肿瘤显著的消退或几乎完全消失。T2信号降低可能反映了腺瘤弥漫性出血引起的脱水。结论：T2加权3TMR对卡麦角林治疗催乳素大腺瘤的疗效评价和监测有重要价值。
Abstract Objective: Cabergoline is the treatment of choice for prolactin (PRL)-producing pituitary adenomas, because of its efficacy in normalizing PRL levels, and inducing tumor shrinkage. The clinical use of 3 T magnetic resonance imaging (MRI) for neuroimaging has rapidly expanded in recent years. In particular, T2-weighted imaging (T2WI) provides high anatomical and contrast resolution. Patients and methods: In this study, serial 3 T MRI with T2WI was utilized during cabergoline treatment of 10 patients with macroprolactinomas. Cabergoline was started at a standard weekly dosage and incrementally adjusted on individual posttreatment PRL values. Results: MRI confirmed tumor shrinkage in all patients during cabergoline treatment. Cabergoline normalized hyperprolactinemia in all but one patient. In six of 10 patients, distinct low-signal-intensity areas were evident throughout the adenomas on T2WI. In four of those six patients, massive low-signal-intensity areas appeared at 1–4 months, after which tumors decreased in size by over 80%. These findings in the early phase of prolactinoma treatment predicted pronounced regression or near-complete disappearance of the tumor. Reduction of T2 intensity possibly reflected dehydration due to diffuse hemorrhage in the adenomas. Conclusion: T2-weighted 3 T MR images are valuable for assessing and monitoring cabergoline treatment of macroprolactinomas.
用每周一次的多巴胺激动剂卡麦角林治疗泌乳素大腺瘤。
DOI：
10.1210/jcem.81.6.8964874
发表时间：
1996
期刊：
The Journal of clinical endocrinology and metabolism
影响因子：
--
作者：
Biller,BM;Molitch,ME;Vance,ML;Cannistraro,KB;Davis,KR;Simons,JA;Schoenfelder,JR;Klibanski,A
通讯作者：
Klibanski,A